RxDoctor Payments DataLook up a doctor →

Jeffrey Freeman, DO

Endocrinology, Diabetes & Metabolism · Springfield, PANPI 1831127091

Payments from drug & device makers

$225,087in general payments, 2019–2025

Across 1,294 payments — averaging $173.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$115K
  • Amarin Pharma, Inc.$44K
  • Bayer$22K
  • Amgen$12K
  • Ascendis Pharma Endocrinology Inc$6K
  • Mannkind Corporation$5K
  • plus $22K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk209$114,549
Amarin Pharma, Inc.111$43,751
Bayer44$21,607
Amgen(2 entities)109$12,459
Ascendis Pharma Endocrinology Inc11$6,259
Mannkind Corporation101$4,504
Valeritas, Inc.10$4,476
Sanofi-aventis U.S. LLC77$3,843
Boehringer Ingelheim29$2,728
Lilly USA, LLC114$2,044
Medtronic(2 entities)41$1,072
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC61$822
Merck36$497
Abbott28$436
Corcept Therapeutics25$414
AstraZeneca(2 entities)22$386
Xeris Pharmaceuticals, Inc.21$374
Novartis19$358
AbbVie15$338
Dexcom, Inc.11$251
Esperion Therapeutics, Inc.15$232
BD10$198
Zealand Pharma US, Inc.11$196
Cequr Corporation3$165
Takeda Pharmaceuticals U.S.A., Inc.3$160
Recordati_rare_diseases_inc.8$156
Intra-sana Laboratories10$154
Tandem Diabetes Care, Inc.7$144
Astellas Pharma US Inc7$133
OPKO Pharmaceuticals, LLC7$133
Shire North American Group Inc8$119
Radius Health, Inc.5$118
Amneal Pharmaceuticals LLC7$108
Kyowa Kirin, Inc.4$108
Amphastar Pharmaceuticals, Inc.7$107
Regeneron1$107
Bigfoot Biomedical Inc1$106
Agepha Pharma FZ LLC6$104
Intuity Medical Inc6$101
Chiesi USA, Inc.6$98
Ipsen Biopharmaceuticals, Inc5$88
Ultragenyx Pharmaceutical Inc.5$81
Ascensia Diabetes Care US Inc.4$76
Insulet Corporation3$75
Pfizer4$73
IBSA Pharma Inc.4$67
Sequel Med Tech, LLC3$63
Regeneron Healthcare Solutions, Inc.4$60
Madrigal Pharmaceuticals2$53
Lifescan, Inc.3$50
Eisai Inc.4$47
Averitas Pharma Inc.2$47
Currax Pharmaceuticals LLC3$46
Johnson & Johnson(2 entities)3$45
Sun Pharmaceutical Industries Inc.3$40
Clarus Therapeutics Inc.2$35
Neurocrine Biosciences, Inc.1$30
Acerus Pharmaceuticals Corporation1$28
Mallinckrodt Hospital Products Inc.1$27
Ionis Pharmaceuticals, Inc.1$21

How this compares

$225,087 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$177,107
Medicare patients
508
Services billed
1,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Springfield

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →